LSE - Delayed Quote EUR

Oxurion NV (0G99.L)

0.0001 0.0000 (0.00%)
At close: April 18 at 8:23 AM GMT+1

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Pascal Ghoson CEO, CFO & Executive Director -- -- --
Philippe Barbeaux Ph.D. Chief Scientific Officer -- -- --
Dr. Andy De Deene M.B.A., M.D. Chief Development Officer -- -- --

Oxurion NV

Gaston Geenslaan 1
Leuven, 3001
Belgium
32 1 675 13 10 https://www.oxurion.com
Full Time Employees: 
20

Description

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Corporate Governance

Oxurion NV’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events